1
|
Kesavadev J, Chandran GB, Basanth A, Krishnan G, Shankar A, Jothydev S. Comparing the benefits of applying a vacuum assisted lancing device in reducing lancing pain, improving self-monitoring frequency and reducing HbA1c in people with diabetes. Diabetes Metab Syndr 2023; 17:102731. [PMID: 36893684 DOI: 10.1016/j.dsx.2023.102731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2022] [Revised: 02/16/2023] [Accepted: 02/19/2023] [Indexed: 03/06/2023]
Abstract
BACKGROUND AND AIMS For most people with diabetes (PwD), lancing fingertips for obtaining a blood sample is unavoidable during blood glucose monitoring (BGM). This study investigated the potential benefits of applying a vacuum over the penetration site immediately, before, during, and after lancing to determine if a vacuum would allow a less painful lancing process from fingertips and alternate sites, while still drawing sufficient blood, thereby allowing PwD to have a painless lancing experience and improving self-monitoring frequency. The cohort was encouraged to use a commercially available vacuum assisted lancing device. Change in pain perception, testing frequency, HbA1c, and future probability of VALD use were determined. METHODS In a 24-week randomized open-label, interventional, cross-over trial, 110 PwD were recruited who used VALD and non-vacuum conventional lancing devices, for 12 weeks each. Percentage reduction in HbA1c, percentage BGM adherence, scores of pain perception, and probability of selecting VALD in the future were measured and compared. RESULTS There was reduction in overall HbA1c values (mean ± SD), (from 9.01 ± 1.68% at baseline to 8.28 ± 1.66%) and individually in T1D (from 8.94 ± 1.77% to 8.25 ± 1.67%) and T2D (from 8.31 ± 1.17% to 8.59 ± 1.30) after using VALD for 12 weeks. Lower pain perception and high probability of using VALD over conventional devices were observed. CONCLUSION The study highlights the benefits of applying a vacuum to the lance site which enhances the effectiveness in reducing and eliminating pain, improving self-monitoring frequency, and lowering HbA1c over non-vacuum conventional devices.
Collapse
Affiliation(s)
- Jothydev Kesavadev
- Department of Diabetes, Jothydev's Diabetes Research Centre, Mudavanmugal, Trivandrum, Kerala, India.
| | - Gopika Beena Chandran
- Department of Diabetes, Jothydev's Diabetes Research Centre, Mudavanmugal, Trivandrum, Kerala, India
| | - Anjana Basanth
- Department of Diabetes, Jothydev's Diabetes Research Centre, Mudavanmugal, Trivandrum, Kerala, India
| | - Gopika Krishnan
- Department of Diabetes, Jothydev's Diabetes Research Centre, Mudavanmugal, Trivandrum, Kerala, India
| | - Arun Shankar
- Department of Diabetes, Jothydev's Diabetes Research Centre, Mudavanmugal, Trivandrum, Kerala, India
| | - Sunitha Jothydev
- Department of Diabetes, Jothydev's Diabetes Research Centre, Mudavanmugal, Trivandrum, Kerala, India
| |
Collapse
|
2
|
Anitha Pavithran A, Ramamoorthy L, Bs S, Murugesan R, Mj K. Comparison of Fingertip vs Palm Site Sampling on Pain Perception, and Variation in Capillary Blood Glucose Level among Patients with Diabetes Mellitus. J Caring Sci 2021; 9:182-187. [PMID: 33409161 PMCID: PMC7770390 DOI: 10.34172/jcs.2020.028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Accepted: 07/08/2020] [Indexed: 12/22/2022] Open
Abstract
Introduction: Glycaemic status of the patient is often monitored using capillary blood glucose test which is fairly accurate. Traditional finger stick sampling is done to obtain sample, which can be painful and may be a barrier for repeated testing. The current study was conducted to compare fingertip and palm site sampling on pain perception, and variation in capillary blood glucose level. Methods: This study was conducted among 284 diabetic patients, who were selected by convenience sampling method. The data was collected by measuring capillary blood glucose levels from fingertip and palm site of the left hand at an interval of 10 minutes using a standard glucometer. The level of pain perceptions was measured with a numerical rating pain scale. Data analysis was accomplished using descriptive analysis, Mann-Whitney U test and Kruskal- Wallis test. Results: The level of pain perception at the palm site (2) was lesser than fingertip (3) which was significant at P < 0.001. 223 (78.52%) of the participants experienced more pain at fingertip than palm site, the difference in the measured capillary blood glucose level between fingertip [mean (SD): 226.65 (87.86)] and palm site [mean (SD): 225.65(92.13)] was minimum. The agreement of palm site was 90.7% in single measurement and 95.1% in average measurement. Conclusion: The present study concludes that, majority of the participants experienced less pain perception at the palm site sampling (alternate site sampling) than fingertip sampling with very minimal variation in the blood glucose level.
Collapse
Affiliation(s)
- Anupama Anitha Pavithran
- Department of Medical Surgical Nursing, College of Nursing, Jawaharlal Institute of Post Graduate Medical Education & Research, Puducherry, India
| | - Lakshmi Ramamoorthy
- Department of Medical Surgical Nursing, College of Nursing, Jawaharlal Institute of Post Graduate Medical Education & Research, Puducherry, India
| | - Suryanarayana Bs
- Department of General Medicine, Jawaharlal Institute of Post Graduate Medical Education & Research, Puducherry, India
| | - Rajeswari Murugesan
- Department of Bio Statistics, Jawaharlal Institute of Post Graduate Medical Education & Research, Puducherry, India Introduction
| | - Kumari Mj
- Department of Medical Surgical Nursing, College of Nursing, Jawaharlal Institute of Post Graduate Medical Education & Research, Puducherry, India
| |
Collapse
|
3
|
Clayton KN, Lee D, Wereley ST, Kinzer-Ursem TL. Measuring biotherapeutic viscosity and degradation on-chip with particle diffusometry. LAB ON A CHIP 2017; 17:4148-4159. [PMID: 29115357 DOI: 10.1039/c7lc00507e] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
In the absence of efficient ways to test drug stability and efficacy, pharmaceuticals that have been stored outside of set temperature conditions are destroyed, often at great cost. This is especially problematic for biotherapeutics, which are highly sensitive to temperature fluctuations. Current platforms for assessing the stability of protein-based biotherapeutics in high throughput and in low volumes are unavailable outside of research and development laboratories and are not efficient for use in production, quality control, distribution, or clinical settings. In these alternative environments, microanalysis platforms could provide significant advantages for the characterization of biotherapeutic degradation. Here we present particle diffusometry (PD), a new technique to study degradation of biotherapeutic solutions. PD uses a simple microfluidic chip and microscope setup to calculate the Brownian motion of particles in a quiescent solution using a variation of particle image velocimetry (PIV) fundamentals. We show that PD can be used to measure the viscosity of protein solutions to discriminate native protein from degraded samples as well as to determine the change in viscosity as a function of therapeutic concentration. PD viscosity analysis is applied to two particularly important biotherapeutic preparations: insulin, a commonly used protein for diabetic patients, and monoclonal antibodies which are an emerging class of biotherapeutics used to treat a variety of diseases such as autoimmune disorders and cancer. PD-based characterization of solution viscosity is a new tool for biotherapeutic analysis, and owing to its easy setup could readily be implemented at key points of the pharmaceutical delivery chain and in clinical settings.
Collapse
Affiliation(s)
- K N Clayton
- School of Mechanical Engineering and Birck Nanotechnology Center, Purdue University, West Lafayette, 47907, USA
| | | | | | | |
Collapse
|
4
|
|
5
|
Abstract
The incidence of insulinopenic diabetes mellitus is constantly increasing, and in addition, approximately a third of all hyperinsulinemic diabetic patients develop insulinopenia. Optimal glycemic control is essential to minimize the risk for diabetes-induced complications, but the majority of diabetic patients fail to achieve proper long-term glucose levels even in clinical trials, and even more so in clinical practice. Compliance with a treatment regimen is likely to be higher if the procedure is simple, painless, and discreet. Thus, insulin has been suggested for nasal, gastrointestinal, and inhalation therapy, but so far with considerable downsides in effect, side effects, or patient acceptance. The stratum corneum is the main barrier preventing convenient drug administration without the drawbacks of subcutaneous injections. Recently, devices with miniaturized needles have been developed that combine the simplicity and discretion of patch-based treatments, but with the potential of peptide and protein administration. As this review describes, initial comparisons with subcutaneous administration now suggest microneedle patches for active insulin delivery are efficient in maintaining glycemic control. Hollow microneedle technology could also prove to be efficient in systemic as well as local delivery of other macromolecular drugs, such as vaccines.
Collapse
Affiliation(s)
- Michael Hultström
- Department of Medical Cell Biology, Division of Integrative Physiology, Uppsala University, Uppsala, Sweden Anaesthesia and Intensive Care, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
| | - Niclas Roxhed
- Micro and Nanosystems, School of Electrical Engineering, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Lina Nordquist
- Department of Medical Cell Biology, Division of Integrative Physiology, Uppsala University, Uppsala, Sweden
| |
Collapse
|
6
|
Scaramuzza A, Cherubini V, Tumini S, Bonfanti R, Buono P, Cardella F, d'Annunzio G, Frongia AP, Lombardo F, Monciotti ACM, Rabbone I, Schiaffini R, Toni S, Zucchini S, Frontino G, Iafusco D. Recommendations for self-monitoring in pediatric diabetes: a consensus statement by the ISPED. Acta Diabetol 2014; 51:173-84. [PMID: 24162715 DOI: 10.1007/s00592-013-0521-7] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2013] [Accepted: 10/01/2013] [Indexed: 11/29/2022]
Abstract
A panel of experts of the Italian Society of Pediatric Endocrinology and Diabetology comprehensively discussed and approved the Italian recommendations regarding self-monitoring of blood glucose, continuous glucose monitoring and other measures of glycemic control in children and adolescents with type 1 diabetes. After an extensive review of the literature, we took these issues into account: self-monitoring blood glucose, continuous glucose monitoring, glycemic variability, glycosuria, ketonuria, ketonemia, glycated hemoglobin, fructosamine and glycated albumin, logbook, data downloading, lancing devices, carbohydrate counting, and glycemic measurements at school. We concluded that clinical guidelines on self-management should be developed in every country with faithful adaptation to local languages and taking into account specific contexts and local peculiarities, without any substantial modifications to the international recommendations. We believe that the National Health Service should provide all necessary resources to ensure self-monitoring of blood glucose and possibly continuous glucose monitoring of all children and adolescents with type 1 diabetes, according to the standards of care provided by these recommendations and internationally.
Collapse
Affiliation(s)
- Andrea Scaramuzza
- Department of Pediatrics, Azienda Ospedaliera, University of Milano, "Ospedale Luigi Sacco," via G.B. Grassi 74, 20157, Milan, Italy,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Wainstein J, Chimin G, Landau Z, Boaz M, Jakubowicz D, Goddard G, Bar-Dayan Y. The use of a CoolSense device to lower pain sensation during finger pricking while measuring blood glucose in diabetes patients--a randomized placebo. Diabetes Technol Ther 2013; 15:688-94. [PMID: 23863047 DOI: 10.1089/dia.2012.0278] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND Patients with type 1 diabetes and a significant portion of patients with type 2 diabetes must use subcutaneous insulin injections, in order to maintain normoglycemia and to prevent immediate and long-term complications. For these patients, testing blood glucose levels more frequently is necessary to safely achieve glycated hemoglobin targets. In the current study, the effects of a CoolSense™ device (CoolSense Medical Ltd., Tel Aviv, Israel) were examined in relieving pain caused by needle-pricking for glucose measurements in adult patients with diabetes. SUBJECTS AND METHODS One hundred seventy-seven patients assessed the severity of pain they experienced during needle-pricking. The patients were randomly divided into an experimental group or a control group that used either a cooled CoolSense instrument or a non-cooled device, respectively. Participants were asked to rank the severity of their pain by a questionnaire developed for this study. Blood glucose levels were monitored as a control. RESULTS The majority of participants (58.3-71.7%; P<0.001) reported significant ache during measurements, the desire for an instrument that relieves pain, and its negative influence on their quality of life. Significant differences were indicated in pain perception between the experimental group and the control group that served as placebo, with no differences in blood glucose measurements in the groups. CONCLUSIONS The CoolSense instrument significantly reduces subjective pain felt by patients and can therefore serve as an additional tool for clinicians to help ease the needle-pricking pain. Future study is needed in order to provide information regarding the practical use of the instrument and its effect on hyper- and hypoglycemia.
Collapse
|
8
|
Abstract
Today, lancing fingertips or alternative sites for obtaining a blood sample for self-monitoring of blood glucose (SMBG) is a standard procedure for most patients with diabetes. The need for frequent lancing and associated discomfort and pain can be seen as a key hurdle for patients to comply with SMBG regimens. This article provides an overview of the status quo and future of lancing, focusing on key areas for future developments driven by customer and market needs. We also review technical issues and provide a background for possible improvements. The act of puncturing the skin with a lancet to obtain a blood sample seems to remain the standard procedure for the foreseeable future, because alternate ways of providing a blood sample have not demonstrated overall superiority (e.g., with laser technology). Other methods, which avoid lancing entirely, have also not gained broad market acceptance (e.g., minimally invasive continuous glucose monitoring) or not shown technical viability (e.g., noninvasive glucose monitoring). In relation to blood glucose (BG) meters and test strips, lancing has been a "stepchild" with regards to commercial attention and development efforts. Nevertheless, significant technological improvements have been made in this field to address key customer needs, including better performance (regarding pain, wound healing, and long-term sensitivity), reduced cost, and higher integration with other components of BG monitoring (e.g., integration of the lancing device with the glucose monitor). From a technical perspective, it is apparent that highly comfortable lancing can be accomplished; however, this still requires fairly advanced and complex devices. New developments are necessary to achieve this level of sophistication and performance with less intricate and costly system designs. Manufacturers' motivation to pursue these developments is compromised by the fact that they might not recoup their development cost on commercial advanced lancing systems through direct profits, but only through its positive influence on adherence and increased more profitable sensor utilization. We believe that two main driving forces will continue to push the evolution of lancing and sampling technology: (1) the need for maximum lancing comfort and (2) the advent of fully integrated systems, realizing a device in which all steps for SMBG are incorporated, thus providing a "one-step" experience. Rendering lancing a "nonissue" will eliminate a key barrier to adherence with appropriate SMBG regimens. Providing sophisticated lancing devices that allow the highest level of comfort and/or seamless blood sampling is key to improving user acceptance. This may have a greater impact on metabolic control than many of the new and expensive antidiabetic drugs.
Collapse
Affiliation(s)
- Lutz Heinemann
- Profil Institut für Stoffwechselforschung GmbHNeuss, Germany
- Profil Institute for Clinical Research, IncSan Diego, California
| | | |
Collapse
|
9
|
Abstract
Without finger pricking, no self-measurement of blood glucose (SMBG) is possible. However, the number of scientific studies dealing with this topic, which is highly relevant for patients, is surprisingly small. This is in sharp contrast to the number of papers about blood glucose meters and SMBG in general. This article highlights a number of aspects that are relevant when it comes to finger pricking and pain. There is a clear improvement in the technology employed in the many different lancing devices that are on the market nowadays; however, no good head-to-head comparison study has been performed to date. The invention of novel devices for finger pricking will most likely bring more attention to this topic.
Collapse
Affiliation(s)
- Lutz Heinemann
- Profil Institut für Stoffwechselforschung, Neuss, Germany.
| |
Collapse
|